204 related articles for article (PubMed ID: 18417073)
1. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides.
Yu R; Yekta B; Vakili L; Gharavi N; Navab M; Marelli D; Ardehali A
Curr Atheroscler Rep; 2008 Apr; 10(2):171-6. PubMed ID: 18417073
[TBL] [Abstract][Full Text] [Related]
2. High-density lipoprotein: antioxidant and anti-inflammatory properties.
Navab M; Yu R; Gharavi N; Huang W; Ezra N; Lotfizadeh A; Anantharamaiah GM; Alipour N; Van Lenten BJ; Reddy ST; Marelli D
Curr Atheroscler Rep; 2007 Sep; 9(3):244-8. PubMed ID: 18241620
[TBL] [Abstract][Full Text] [Related]
3. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature.
Navab M; Reddy ST; Van Lenten BJ; Buga GM; Hough G; Wagner AC; Fogelman AM
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2553-60. PubMed ID: 23077141
[TBL] [Abstract][Full Text] [Related]
4. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.
Imaizumi S; Navab M; Morgantini C; Charles-Schoeman C; Su F; Gao F; Kwon M; Ganapathy E; Meriwether D; Farias-Eisner R; Fogelman AM; Reddy ST
Circ J; 2011; 75(7):1533-8. PubMed ID: 21628835
[TBL] [Abstract][Full Text] [Related]
5. The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis.
Navab M; Anantharamaiah GM; Fogelman AM
Trends Cardiovasc Med; 2008 Feb; 18(2):61-6. PubMed ID: 18308197
[TBL] [Abstract][Full Text] [Related]
6. The effect of HDL mimetic peptide 4F on PON1.
Vakili L; Hama S; Kim JB; Tien D; Safarpoor S; Ly N; Vakili G; Hough G; Navab M
Adv Exp Med Biol; 2010; 660():167-72. PubMed ID: 20221879
[TBL] [Abstract][Full Text] [Related]
7. [Changes in biological functions of high-density lipoprotein after abnormal modification].
Qu H; Yu Y; Qin SC; Song GH
Sheng Li Xue Bao; 2017 Apr; 69(2):225-234. PubMed ID: 28435982
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management.
Shah PK; Chyu KY
Trends Cardiovasc Med; 2005 Nov; 15(8):291-6. PubMed ID: 16297766
[TBL] [Abstract][Full Text] [Related]
9. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.
Navab M; Berliner JA; Subbanagounder G; Hama S; Lusis AJ; Castellani LW; Reddy S; Shih D; Shi W; Watson AD; Van Lenten BJ; Vora D; Fogelman AM
Arterioscler Thromb Vasc Biol; 2001 Apr; 21(4):481-8. PubMed ID: 11304461
[TBL] [Abstract][Full Text] [Related]
10. [Protective role of high density lipoproteins in sepsis: basic issues and clinical implications].
Contreras-Duarte S; Varas P; Awad F; Busso D; Rigotti A
Rev Chilena Infectol; 2014 Feb; 31(1):34-43. PubMed ID: 24740772
[TBL] [Abstract][Full Text] [Related]
11. Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease.
Navab KD; Elboudwarej O; Gharif M; Yu J; Hama SY; Safarpour S; Hough GP; Vakili L; Reddy ST; Navab M; Vaziri ND
Curr Pharm Des; 2011; 17(1):17-20. PubMed ID: 21222643
[TBL] [Abstract][Full Text] [Related]
12. Systemic inflammation, intestine, and paraoxonase-1.
Vakili L; Navab KD; Shabihkhani M; Pourtabatabaei N; Vazirian S; Barseghian Z; Seyedali S; Hough G
Adv Exp Med Biol; 2014; 824():83-8. PubMed ID: 25038995
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of acute infection-induced endothelial dysfunction and its potential mediators.
Kilickap M; Goksuluk H; Candemir B; Kaya CT; Ozcan OU; Turhan S; Vurgun K; Ozdemir AO; Erol C
Acta Cardiol; 2011 Oct; 66(5):581-7. PubMed ID: 22032051
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
Sherman CB; Peterson SJ; Frishman WH
Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
[TBL] [Abstract][Full Text] [Related]
15. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST
Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738
[TBL] [Abstract][Full Text] [Related]
16. The role of high-density lipoprotein in inflammation.
Navab M; Anantharamaiah GM; Fogelman AM
Trends Cardiovasc Med; 2005 May; 15(4):158-61. PubMed ID: 16099381
[TBL] [Abstract][Full Text] [Related]
17. Potential restoration of HDL function with apolipoprotein A-I mimetic peptide in end-stage renal disease.
Kaysen GA
Kidney Int; 2009 Aug; 76(4):359-61. PubMed ID: 19644477
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for low high-density lipoproteins.
Hafiane A; Kellett S; Genest J
Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):134-9. PubMed ID: 24535232
[TBL] [Abstract][Full Text] [Related]
19. Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein.
Smith JD
J Clin Lipidol; 2010; 4(5):382-8. PubMed ID: 21076633
[TBL] [Abstract][Full Text] [Related]
20. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders.
Getz GS; Wool GD; Reardon CA
Curr Pharm Des; 2010; 16(28):3173-84. PubMed ID: 20687877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
